Longevity Biomedical

Executive Summary

Longevity Biomedical, founded in 2019 and headquartered in Bothell, Washington, is a privately held biotechnology company dedicated to extending human healthspan through regenerative medicine and cardiovascular innovation. The company's mission is to develop products and services that enable longer, healthier lives, positioning itself at the intersection of two high-growth therapeutic areas. As a preclinical-stage entity with no disclosed pipeline or funding history, Longevity Biomedical operates with a lean profile but benefits from the tailwinds of increasing interest in longevity and regenerative therapies. Its strategic focus on cardiovascular disease, a leading cause of death globally, offers significant market potential if its platform can demonstrate preclinical proof-of-concept. However, the lack of publicly available data on specific programs, financial backing, or partnerships introduces substantial uncertainty regarding near-term value inflection points. The company's future trajectory hinges on securing initial funding, advancing candidates toward IND-enabling studies, and establishing credibility within the competitive longevity biotech landscape.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026Lead Program Preclinical Proof-of-Concept Data45% success
• Q1 2027Strategic Partnership or Licensing Deal30% success